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Abstract
Background: Sphingolipids (SL), in particular sphingomyelin (SM) are important components of
milk fat polar lipids. Dietary SM inhibits cholesterol absorption in rats (Nyberg et al. J Nutr Biochem.
2000) and SLs decrease both cholesterol and TG concentrations in lipid- and cholesterol fed
APOE*3Leiden mice (Duivenvoorden et al. Am J Clin Nutr. 2006). This human study examines effects
of a butter milk formulation enriched in milk fat globule membrane material, and thereby in SLs, on
blood lipids in healthy volunteers. In a four week parallel group study with 33 men and 15 women
we examined the effects of an SL-enriched butter milk formulation (A) and an equivalent control
formulation (B) on plasma lipid levels. Plasma concentrations of HDL and LDL cholesterol,
triacylglycerols (TG), apolipoproteins AI and B, and lipoprotein (a) were measured. The daily dose
of SL in A was 975 mg of which 700 mg was SM. The participants registered food and drink intake
four days before introducing the test formula and the last four days of the test period.
Results:  A daily increase of SL intake did not significantly influence fasting plasma lipids or
lipoproteins. In group B TG, cholesterol, LDL, HDL and apolipoprotein B concentrations increased,
however, but not in group A after four weeks. The difference in LDL cholesterol was seen primarily
in women and difference in TG primarily in men. No significant side effects were observed.
Conclusion: The study did not show any significant decrease on plasma lipids or lipoprotein levels
of an SL-enriched formulation containing 2-3 times more SL than the normal dietary intake on
cholesterol, other plasma lipids or on energy intake. The formulation A may, however, have
counteracted the trend towards increased blood lipid concentrations caused by increased energy
intake that was seen with the B formulation.
Background
High concentrations of plasma cholesterol, especially low
density lipoproteins (LDL) and/or triglycerides (TG) and
lipoprotein a (Lp (a)) [1] are well known risk factors for
cardiovascular disease (CVD) whereas HDL levels are
inversely correlated to risk. Plasma lipid and lipoprotein
levels are determined by genetic predisposition as well as
lifestyle and dietary levels can be influenced by numerous
dietary factors acting via several mechanisms. To reduce
intestinal cholesterol absorption by dietary factors is an
important way to improve blood lipid concentrations. A
successful example is that foods containing plant sterols
can reduce LDL cholesterol levels by 10-20% [2].
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Sphingomyelin (SM) is a polar lipid in the milk fat glob-
ule membrane (MFGM) and accounts for 25% of the
membrane lipids in bovine milk [3]. SM is also a precur-
sor to the bioactive sphingolipid signaling molecules cera-
mide, sphingosine and sphingosine-1-phospate [4]. Both
dietary and membrane SM interact strongly with choles-
terol [5]. Studies on rats have shown that dietary SM
inhibits cholesterol absorption and the inhibition is more
effective with milk SM than egg SM [6,7]. Dietary SL
decreased both cholesterol and TG concentrations in
lipid- and cholesterol fed ApoE Leyden mice [8].
Milk fat contains 2-3% of polar lipids and the Western
dietary intake of SM from bovine milk is approximately 4-
12 mg/dl [9]. Buttermilk and whey are two liquid remains
from manufacturing of butter and cheese, which have in
recent years gained more interest as a source of bioactive
compounds such as MFGM [10]. During the process of
churning and cheese making an excess of polar MFGM
membrane material is released in the buttermilk and
whey. New technologies for enrichment of MFGM,
including the one developed by Arla Foods and used in
this study, have emerged. There are no previous studies on
long term intake of SL in humans due to lack of suitable
formulations.
In this study we examine the effects of a tasty milk drink-
like formulation enriched in polar lipids from buttermilk.
The effects on plasma cholesterol, TG, HDL, LDL and
apolipoproteins A1 (apoA1), B (apoB) and Lp(a) over 4
weeks daily intake of 2-3 times the normal daily intake of
SL were examined. The main hypothesis was that the long
term intake of SM enriched drink would inhibit intestinal
cholesterol uptake with lowered total plasma- and LDL-
cholesterol as outcome. We also asked whether TG metab-
olism is beneficially influenced, as in the apoE Leyden
mice [8].
Methods
Drinks
The test drink A used in this study were based on proc-
essed and enriched butter milk and contains 4,0% Lacpro-
dan PL-20 powder from Arla Foods amba containing 20%
milk phospholipids originating from the serum phase of
butter oil production (Table 1). The test drink (A) con-
tains 700 mg SM, 180 mg glucoceramides, and 95 mg gan-
gliosides (mainly GD3). Total amount of SL 975 mg in
one portion of about 350 ml. A placebo drink (B) was
made by 5,82% skim milk powder containing 37% pro-
tein in which the phospholipids have been replaced by 2/
3 of egg PL isolate by Fresenius GmbH and 1/3 butter oil.
The placebo drink contains 119 mg of SL per portion. The
cholesterol content was adjusted to be the same in both
drinks, i.e. 11 mg per 100 ml or 38 mg per serving.
The drinks has been subjected to heat treatment at 143C
for 6 s and poured into Tetra Brick containers under asep-
tic conditions. The sterility of the drink has been verified
by certified control laboratory. Test and placebo drink was
manufactured at Trenums Industries, Tingsryd, Sweden,
under supervision of Arla-experts. Trenums is an
approved facility for manufacturing of food items. The
drinks were stored in refrigerator and it is recommended
to shake it a little before consumption.
Study design
This study includes 48 healthy persons between 20 and 65
years of age, that were healthy according to their knowl-
edge, and as indicated by the initial laboratory screening
described below (Table 2). The participants were distrib-
Table 1: Composition of test drink A and placebo drink B.
A (per 100 g) A (daily ) B (per 100 g) B (daily)
Total lipid of which polar lipids SL 1,12 g 3,7 g 1,12 g 3,7 g
800 mg 2,8 g 768 mg 2,7 g
295 mg 975 mg 34 mg 119 mg
Protein 2,4 g 8,4 g 2,2 g 7,7 g
Sucrose 4,2 g 14,7 g 4,2 g 14,7 g
Lactose 2,7 g 9,5 g 2,7 g 9,5 g
Maltodextrin 2,0 g 7 g 2,0 g 7 g
Cholesterol 11 mg 38 mg 11 mg 38 mg
Total Energy 230 KJ 806 KJ 230 KJ 806 KJ
The amounts are shown per 100 g and the daily intake of 350 ml. The polar lipids in A are milk phospholipids and in B 66% are egg phospholipids.Lipids in Health and Disease 2009, 8:44 http://www.lipidworld.com/content/8/1/44
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uted as follows: 33 men of whom 20 had test drink A, and
15 women of whom 9 had test drink A.
Voluntary participants were recruited through announce-
ments on local intranet and advertisement in different
work places in Lund. All participants gave their written
informed consent prior to the study. The study was
approved by the Regional Human Ethics Committee of
Lund-Malmö.
The study was over a five week period of which the first
week was a run in period when they kept a compulsory
food diary of their intake for 4 days. The diary was
designed by the Department of Clinical Nutrition at Lund
University Hospital. After the first week participants drank
the test drink or placebo drink every day for four weeks.
The participants got a supply of 28 portions to be kept
refrigerated at home and consume half a portion (about
175 ml) in the morning and the last half in the evening.
Both test drink and placebo drink were well tolerated and
palatable.
The participants begin the five week study by providing
fasting blood samples. The morning the same day they
start with test/placebo drink they also provide blood sam-
ples. Blood samples are taken again after two weeks intake
of test/placebo drink and again on the last day of the
study. The participants give blood samples all together
four times during the study and all of them are taken fast-
ing in the morning at the Department of Clinical Chemis-
try, University Hospital of Lund.
Throughout the study the participants continued their
normal life with no restrictions. They were instructed to
report intake of alcohol and pharmaceutical drugs but
they were not instructed to report exercise.
Analysis
Fasting blood samples were analyzed for TG, total choles-
terol, HDL, LDL, apoA1 and apoB as well as for liver val-
ues, CRP, hemoglobin, white blood cell count and
platelet count at Department of Clinical Chemistry, Uni-
versity Hospital of Lund, Sweden http://www.analys
forteckning.usil.se. Two ml EDTA plasma was kept frozen
for further analysis of Lp (a).
All participants kept the diaries according to instructions
and the intake was analyzed by the use of Dietist XP soft-
ware with the Swedish National Food Administration
database (20080306) (Kost och Näringsdata, Sweden).
Dietary intakes were related to recommended Swedish
dietary guidelines [11].
Statistics
Values from clinical data are presented in figures as mean
± SEM of normalized values, however all statistical analy-
ses are done with absolute values. Results of the statistical
evaluation are presented in the text. Statistical analysis of
Table 2: Characteristics of the 48 subjects.
Men n = 33 Women n = 15
A(20) B(13) A(9) B(6)
Age 47,4 ± 2,9 42,9 ± 4,6 45,1 ± 3,6 43,3 ± 5,7
BMI 24,1 ± 0,4 24,9 ± 0,5 24,0 ± 1,0 24,5 ± 1,6
Length, m 1,78 ± 1,6 1,79 ± 1,6 1,69 ± 1,9 1,68 ± 3,5
Weight, kg 76,8 ± 1,9 80,2 ± 2,4 68,3 ± 3,1 69,8 ± 6,0
Starting TG in mmol/L 1,15 ± 0,15 0,96 ± 0,12 0,92 ± 0,13 0,67 ± 0,07
Starting CHOL in mmol/L 4,86 ± 0,20 4,49 ± 0,23 4,70 ± 0,29 4,47 ± 0,23
Starting LDL in mmol/L 3,31 ± 0,18 2,95 ± 0,22 3,09 ± 0,27 2,68 ± 0,15
Starting HDL in mmol/L 1,33 ± 0,07 1,34 ± 0,08 1,50 ± 0,09 1,80 ± 0,20
Starting ApoA1 in g/L 1,39 ± 0,03 1,37 ± 0,05 1,51 ± 0,07 1,60 ± 0,14
Starting ApoB in g/L 0,88 ± 0,05 0,79 ± 0,05 0,82 ± 0,06 0,69 ± 0,03
Values are mean ± SEM (number in each group).Lipids in Health and Disease 2009, 8:44 http://www.lipidworld.com/content/8/1/44
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the three different time points within each group were
done with repeated measures ANOVA and Bonferroni as
post test. Comparisons of data before and after intake
within each group was done with paired students t-test
and unpaired t-test was used to calculate if there were any
difference between lipid concentrations after the study
period for group A vs. group B. Values are considered dif-
ferent for * p < 0,05, ** p < 0,001, *** p < 0,0001. Results
from dietary intake are mean of four days intake from
each person. Differences in intake both with and without
test drink are analyzed with paired Students t-test. Graph
Pad Prism 5. GraphPad Software Inc. San Diego, USA was
used as soft ware.
Results
Plasma lipids
The characteristics of the participants are described in
table 2 and did not differ between test- and placebo
groups. After four weeks of daily intake of a SM-enriched
milk drink (A) or an equivalent SL free control formula-
tion (B) we found no significant changes between group
A and B neither in the concentrations of cholesterol, LDL,
HDL, TG and apoA1 and apoB nor in the lipid intake (Fig-
ures 1, 2, 3 and 4). In all participants (Figure 1) the blood
lipid concentrations in group B after intake where gener-
ally higher than starting values for total cholesterol (p =
0,072), LDL cholesterol (p = 0,084) and TG (p = 0,098)
with much less changes in group A. There was a significant
decrease in Apo A1 (p = 0,005) after intake in group A
compared to starting value.
In men (Figure 2) there were trends such as increases in
plasma cholesterol values and the concentrations of
plasma TGs increased by 26% in the placebo group but
remained unchanged in the test group but the difference
was not significant (p = 0,082) which may be related
increased energy intake (Table 3). The cholesterol, HDL
LDL concentrations were all slightly elevated by 0,6-4,8%
in both placebo and test group. ApoA1 was decreased in
group A compared to starting values (p = 0,055) and
remained unchanged in group B. Apo B was also slightly
increased in group B but not in group A after intake.
The difference between group A and B in women (Figure
3) was not significant for any plasma lipid but there were
trends such as increases in plasma LDL (p = 0,056) and
HDL cholesterol (p = 0,070) in group B compared to
group A. There were some differences in initial blood lipid
concentrations between group A and B in women. In
group B LDL and TG are 13% and 27% lower than in
group A but HDL is 20% higher in B than in group A
(Table 2) but all concentrations are within normal range
both before and after the study. In group B all blood lipid
concentrations except apoA1 were increased after the test
period and the increase in HDL by 4,8% was statistically
different (p = 0,018) compared to starting values. In group
A there were decreased concentrations of total cholesterol,
LDL and HDL by 1,2, 3,5 and 1,9% respectively which can
be related to a decrease of cholesterol intake by 6% but
not to increased intake of saturated fat (Table 4). Apolipo-
protein B concentration decreased in group A compared
to starting concentrations but not significantly (p =
0,083). The increase in plasma TG concentration in both
groups coincides with the increased energy and fat intake.
There was a minor increase in the apoB/apoA1 ratios in
both groups (Figure 4). In men this increase was predom-
inantly in group A as opposed to women where group B
had the highest increase after four weeks. The concentra-
tions of Lp (a) varied considerably between below 60 and
489 mg/ml in both men and women but no significant
changes were seen after four weeks (Table 5). For women
in group A Lp(a) concentration was reduced by 10% but
increased in all other groups after four weeks.
Food intake
From analysis of the food diaries before and in the end of
the 4 week period the energy intake, cholesterol and fat
intake were increased at the end of the test period in both
groups, which partly can be explained by the addition of
test drink to their normal diet (Table 6). The participants
were not instructed to inform us whether the test drink
replaced something in their normal diet or if it was just
added. The energy intake by men (Table 3) was increased
by 5.6% in the placebo group and decreased by 1.2% in
the test group. When we include the energy from the test
drink the increased intake in group B was significantly
higher after four weeks (p = 0.03). In women (Table 4) the
energy intake was increased in both groups even without
including the test drink. When we include the test drink
the intake in group A was significantly higher after four
weeks (p = 0.017) (Table 4). The cholesterol intake was
reduced by 6% in the test groups of both men and women
and by 9% within the men in the placebo group (Table 3
and 4). The women in the placebo group had an increased
intake of cholesterol by 9%. When we include the 38 mg
cholesterol from the test drinks, all groups increase their
cholesterol intake. The fat intake was increased or almost
unchanged among all participants in both groups,
whether the test drink was included or not (Table 6). The
intake of saturated fat was increased among women in
both groups but remained stable in men with a minor
decrease of 2% in the test group (Table 3 and 4). Overall,
the difference in total energy intake, cholesterol and satu-
rated fat intake corresponds to the changes in the blood
lipid concentrations. In men, drink A tends to give a less
health promoting response in the blood lipids with regard
to cholesterol and LDL than in women. As side effects,Lipids in Health and Disease 2009, 8:44 http://www.lipidworld.com/content/8/1/44
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This figure shows plasma lipids in all participants as differences from starting value Figure 1
This figure shows plasma lipids in all participants as differences from starting value. Figure 1a) Shows total plasma 
cholesterol, b) Plasma LDL cholesterol, c) plasma HDL cholesterol, d) plasma triacylglycerol, e) apolipoprotein A1 and f) shows 
apolipoprotein B. A-d are in mmol/L and e-f in g/L. All values are mean ± SEM at fasting state. Red label represents the group 
taking test drink A, n = 29 and green labels represent the group taking placebo drink B, n = 19.
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This figure shows plasma lipids in men as differences from starting value Figure 2
This figure shows plasma lipids in men as differences from starting value. Figure 2a) Shows total plasma cholesterol, 
b) Plasma LDL cholesterol, c) plasma HDL cholesterol, d) plasma triacylglycerol, e) apolipoprotein A1 and f) shows apolipopro-
tein B. A-d are in mmol/L and e-f in g/L. All values are mean ± SEM at fasting state. Red label represents the group taking test 
drink A, n = 20 and green labels represent the group taking placebo drink B, n = 13.
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This figure shows plasma lipids in women as differences from starting value Figure 3
This figure shows plasma lipids in women as differences from starting value. Figure 3a) Shows total plasma choles-
terol, b) Plasma LDL cholesterol, c) plasma HDL cholesterol, d) plasma triacylglycerol, e) apolipoprotein A1 and f) shows apol-
ipoprotein B. Values in a-d are in mmol/L and e-f in g/L. All values are mean ± SEM at fasting state. Red label represents the 
group taking test drink A, n = 9 and green labels represent the group taking placebo drink B, n = 6.
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The figure shows ratios of ApoA1/Apo B Figure 4
The figure shows ratios of ApoA1/Apo B. Figure 4a) shows all participants, b) men, c) women. Values are mean ± SEM 
and presented as differences from starting value. Red label represent test group A and green label represent placebo group B.
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four persons in group A and one person in group B
reported minor gut discomfort such as pain or irregular
movement.
Discussion
This study investigates whether a daily intake of a SL-
enriched milk drink affects fasting blood lipids in 48 sub-
jects (33 men and 15 women) over 4 weeks. The back-
ground to this study was that SM was found to inhibit
cholesterol absorption in rats [6] and the ability of several
dietary SLs to decrease plasma cholesterol and TG and
liver accumulation of TG in apoE Leyden mice on a fat-
and cholesterol rich diet [8]. Another important factor
was that a new formulation, prepared by a dairy technol-
ogy that does not involve organic solvent extraction and is
simple and cost effective, had become available.
The major finding in our study was that no significant
plasma lipid lowering effects of the SL rich formulation A
was found since there was no decrease in atherogenic
plasma lipids or lipoproteins after the four week treat-
ment.
There were, however, trends towards increased concentra-
tions of total plasma cholesterol, LDL, HDL, apo B and TG
in group B, which were not seen in group A.
To explain this finding an important aspect is that partic-
ipants in both groups increased their energy intake and to
some extent the intake of saturated fat and cholesterol
(Table 6). It is not specified by the participants whether
the test drink replaced a regular food item such as another
milk product or was added to their normal diet, but
according to their food registrations we believe that they
mainly added the test drink. One can therefore argue that
formulation A may have counteracted an increase in total
cholesterol, apoB and TG, related mainly to an increased
energy intake which provides some support for a positive
Table 3: Differences in daily intake of total energy, cholesterol and saturated fat in men four days before and the last four days of the 
study period. 
Group A before
n = 18
Group A
after
n = 18
Difference (%) Group B before
n = 13
Group B after
n = 13
Difference (%)
Total energy intake (KJ) 9143 ± 474 9040 ± 482 - 1,2 8754 ± 516 9244 ± 469 + 5,6
Including testdrink 9801 ± 482 +7,2 10005 ± 469* +14,3
Cholesterol intake (mg) 304 ± 27 286 ± 26 -5,9 323 ± 41 295 ± 41 -8,7
Including test drink 319 ± 26 +4,9 328 ± 41 +1,5
Saturated fat intake (g) 34,3 ± 2,9 33,6 ± 3,5 -2,0 35,2 ± 3,6 35,4 ± 2,82 + 0,1
Total fat intake (g) 85,4 ± 6,2 83,7 ± 7,6 -1,96 87,7 ± 7,4 86,2 ± 4,2 -1,71
Including testdrink 87,9 ± 7,6 +2,93 90,4 ± 4,2 +2,7
Differences before and after intake in each group was statistically analyzed using students paired t-test. * p < 0,01. ** p = < 0,001. *** p = < 0,0001. 
The values are mean ± SEM and the values for each subject are mean of four days of food registration.
Table 4: Differences in daily intake of total energy, cholesterol, saturated- and total fat in women four days before and the last four 
days of the study period. 
Group A before
n = 9
Group A after
n = 9
Difference (%) Group B before
n = 6
Group B after
n = 6
Difference (%)
Total energy intake (KJ) 7448 ± 601 8127 ± 509 + 9,1 7957 ± 484 8149 ± 898 + 2,4
Including testdrink 8888 ± 509* +19,3 8910 ± 898 +12,0
Cholesterol intake (mg) 266 ± 18 250 ± 34 -6,0 256 ± 26 279 ± 65 + 9,0
Including testdrink 283 ± 34 +6,4 312 ± 65 +21,9
Saturated fat intake (g) 31,4 ± 3,7 34,4 ± 3,2 +9,6 31,0 ± 4,04 35,2 ± 5,9 + 13,5
Total fat intake (g) 71,7 ± 7,8 82,0 ± 8,1 +14,4 73,2 ± 8,7 78,8 ± 11,7 +7,7
Including testdrink 86,2 ± 8,1 +20,2 83 ± 11,7 +9,8
Differences before and after intake in each group was statistically analyzed using students paired t-test. * p < 0,01. ** p = < 0,001. *** p = < 0,0001. 
The values are mean ± SEM and the values for each subject are mean of four days of food registration.Lipids in Health and Disease 2009, 8:44 http://www.lipidworld.com/content/8/1/44
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effect of the milk polar lipids. ApoB/apoA1 ratios devel-
oped, however similar in the two groups (Figure 4).
Comparing the responses for the two formulations in
men and women revealed that formulation B consistently
increased many of the blood lipids whilst formulation A
did not. Only the concentration of TG remained unaf-
fected between the two groups. In group B the increase of
TG was accounted for by men and the increased LDL and
apoB concentrations were to a larger part accounted for by
women. Women in group B were few and happened to
have lower average starting concentration of TG than
group A. This could make the TG response less sensitive to
increased energy intake, which might decrease any differ-
ence between group A and B after four weeks. Overall, the
variations we observe for the different blood lipids in the
placebo groups after four weeks resemble effects that you
get from intake of milk lipids rich in saturated fatty acids.
This pattern was not observed in group A where, all
together, very little effect from the test drink was seen.
Several studies have shown that the level of the independ-
ent risk factor Lp(a), although primarily genetically deter-
mined, may also be influenced by external factors. In milk
context it was earlier reported that casein, in contrast to
soy protein significantly decreased Lp(a)[12]. We there-
fore also compared the response of Lp(a) to the two for-
mulations and found no difference between participants
in group A and B. In women Lp(a) decreased, however, in
response to the A- and increased to B formulation which
was opposite the results in men where the increase was
seen in A. Although not conclusive the study indicate sex
differences that needs to be further investigated. Future
studies should also consider that other components in
milk might influence Lp(a).
There are several possible reasons why no clear positive
effect of the SL formulation was seen on blood lipids in
this study. For one thing, the outcome may reflect that SLs
do not affect absorption of endogenous cholesterol which
is necessary to achieve an effect on plasma cholesterol in
humans. Older studies in which plant sterols were fed in
an unesterified form provided little support for a signifi-
cant cholesterol lowering effect, whereas plant sterol mar-
garines in which sterol esters are mixed into dietary lipids
are more effective [13]. Another factor is the dose given. In
rodents digestion of SM is extended and has a limited
capacity and the physical interaction between SM and
Table 5: Concentration of plasma lipoprotein (a). 
Test group before Test group after Difference (%) Placebo group before Placebo group after Difference (%)
Men 166 ± 51
(161)
182 ± 47 + 9,6 166 ± 38
(11)
168 ± 70 + 1,2
Women 127 ± 26
(81)
114 ± 28 - 10,2 165 ± 44
(6)
207 ± 64 + 25
All 153 ± 35
(241)
159 ± 33 + 3,9 169 ± 28
(17)
181 ± 34 + 7,1
Missing values are due to sample hemolysis and could not be measured.
The table shows lipoprotein (a) concentrations in men and women before and after intervention period. The values are mg/L and mean ± SEM 
(number of subjects).
Table 6: Differences in daily intake before and after the study period. 
Group A before
n = 27
Group A
after
n = 27
Difference (%) Group B before
n = 19
Group B after
n = 19
Difference (%)
Total energy intake (KJ) 8578 ± 399 8735 ± 367 + 1,83 8502 ± 387 8898 ± 431 + 4,66
Including testdrink 9496 ± 367 + 10,7 9659 ± 431 +13,6
Cholesterol intake (mg) 291 ± 19 274 ± 20 -5,91 302 ± 30 290 ± 34 -3,97
Including testdrink 307 ± 20 + 5,5 323 ± 34 +7,0
Saturated fat intake (g) 33,3 ± 2,3 33,8 ± 2,5 +1,56 33,9 ± 2,8 35,3 ± 2,6 + 4,25
Total fat intake (g) 80,8 ± 4,9 83,2 ± 5,6 +2,89 83,1 ± 5,9 83,8 ± 4,6 +0,9
Including testdrink 87,4 ± 5,6 +6,6 88 ± 4,6 +5,9
The table shows intake of total energy, cholesterol and saturated fat in all participants. Differences before and after intake in each group was 
statistically analyzed using students paired t-test. * p < 0,01. ** p = < 0,001. *** p = < 0,0001. The values are mean ± SEM and the values for each 
subject are mean of four days of food registration before and the last four days.Lipids in Health and Disease 2009, 8:44 http://www.lipidworld.com/content/8/1/44
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cholesterol may be important. In contrast, humans
express the key digestive enzyme for SM, alkaline sphingo-
myelinase also in the liver and secrets it in bile [14].
Sphingomyelin digestion might consequently be more
efficient in humans.
In a recent study on ileostomy patients we found that after
feeding 50-250 mg milk SM in a breakfast meal the over-
whelming part had been digested and the cholesterol/SM
ratios in the ileostomy content was high, although some
increases in ileostomy output of SM species and ceramide
were observed (L Ohlsson et al. submitted). The chosen
dose of SL in this study (700 mg SM, 975 mg total, approx
1% of dietary lipids) is 2-3 times a normal Western dietary
daily intake, which we believed large enough to test for
possible effects. Considering the dose of plant sterols in
margarines that is necessary to achieve decreases of total
and LDL cholesterol, one may argue that the dose used
here is not very high. Another factor is that SLs contain sat-
urated fatty acids and the sphingoid bases are converted
mainly to palmitic acid after absorption. They are thus a
source of saturated fatty acids that raises LDL cholesterol
although the quantity should not be sufficient to have sig-
nificant influence in this study. Furthermore, both formu-
lations contained a daily dose of 36 mg cholesterol which
could be calculated to increase plasma cholesterol by
0,02-0,03 mmol/l [15].
Studies on apo BE receptor gene knockout mice, a model
that is very sensitive to dietary cholesterol, suggested that
SM-rich diet might raise plasma cholesterol levels and
thereby enhance arteriosclerosis [16]. The finding in this
study that LDL cholesterol exhibited some increase in the
B but not in the A group indicate that these findings may
not be relevant to healthy humans. Another important
conclusion was that the formulations were both well tol-
erated and the only type of side effects reported were
"Mild abdominal symptoms", which were reported by
four persons in group A and one in B. We cannot exclude
that the composition of formulation A may have contrib-
uted to this symptom, but the relation is uncertain since
non specific symptoms like this can be caused by lactose
even in individuals with normal lactase levels.
There is rather strong evidence that consumption of milk
counteract colon cancer [17]. This effect may in part be
ascribed to the calcium and vitamin D content [18]. Since
several animal studies have found antitumor effects in the
gut with SM or combinations of SL that occur in milk [19-
21], there is reason to explore butter milk based formula-
tions high in both calcium, vitamin D and polar lipids for
anticarcinogenic and anti-inflammatory effects in human
gut.
Polar milk lipids also contain phosphatidylcholine, phos-
phatidyl serine and smaller amounts of other glycerolip-
ids. Studies with high doses of soy phospholipids have
shown an LDL lowering effect, which may be due to high
content of linoleic acid [22]. A minor raise in HDL2 by a
high dose (15 g/day) of soy phospholipids was observed
[23]. Consequently we do not expect the milk glycero-
phospholipids to exert any significant effect on the results
in this study. However, a study by Sjogren et al
[24]showed that milk consumption is associated with a
more favourable size of the LDL particles. Further studies
of SL enriched milk polar lipids on HDL and LDL compo-
sition may thus be motivated.
Conclusion
This study did not provide strong proof of a lipid lowering
effects of SL-enriched milk polar lipids, although it sup-
ports that formulation A counteracted TG and TDL
increases related to an increased energy and fat intake. The
SL rich formulation was well tolerated which promotes
further studies that consider dose as well as synergies with
other factors that may lower cholesterol absorption. Such
studies should include hyper lipidemic patients and
should consider also possible anti-inflammatory and anti-
tumour effects in humans.
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